Insider Buying: Biodesix, Inc. (NASDAQ:BDSX) Director Acquires $234,000.00 in Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack W. Schuler purchased 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was bought at an average cost of $1.17 per share, with a total value of $234,000.00. Following the completion of the purchase, the director now owns 31,094,935 shares of the company’s stock, valued at $36,381,073.95. This represents a 0.65 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Biodesix Trading Up 6.7 %

Biodesix stock opened at $1.28 on Friday. Biodesix, Inc. has a 12 month low of $1.11 and a 12 month high of $2.21. The company has a market capitalization of $186.20 million, a price-to-earnings ratio of -3.28 and a beta of 1.22. The business’s fifty day simple moving average is $1.57 and its two-hundred day simple moving average is $1.61. The company has a current ratio of 3.40, a quick ratio of 3.40 and a debt-to-equity ratio of 1.30.

Biodesix (NASDAQ:BDSX) last announced its quarterly earnings results on Friday, November 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). The company had revenue of $18.15 million for the quarter, compared to analysts’ expectations of $18.45 million. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. During the same quarter in the previous year, the business posted ($0.12) EPS. As a group, equities analysts predict that Biodesix, Inc. will post -0.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Biodesix

Several institutional investors and hedge funds have recently made changes to their positions in BDSX. Opaleye Management Inc. lifted its position in Biodesix by 7.7% in the 1st quarter. Opaleye Management Inc. now owns 534,657 shares of the company’s stock valued at $765,000 after acquiring an additional 38,157 shares in the last quarter. AIGH Capital Management LLC raised its stake in shares of Biodesix by 74.0% in the second quarter. AIGH Capital Management LLC now owns 5,779,812 shares of the company’s stock worth $8,843,000 after purchasing an additional 2,458,727 shares during the last quarter. Farallon Capital Management LLC bought a new position in shares of Biodesix during the second quarter valued at $2,874,000. CVI Holdings LLC bought a new stake in Biodesix in the 2nd quarter worth about $59,000. Finally, Perceptive Advisors LLC bought a new stake in Biodesix in the 2nd quarter worth about $3,326,000. Institutional investors own 20.96% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Scotiabank began coverage on shares of Biodesix in a research report on Monday, September 16th. They set a “sector outperform” rating and a $3.00 price target for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $3.06.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.